{"preliminary_commentary":{"by_channel":{"x_thread":2,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["palbociclib"]],"indication":"early invasive lobular or ductal breast cancer","name":"PELOPS","nct_id":"NCT02764541","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=pelops-nct02764541. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Tamoxifen is given in the Window of Treatment phase for 2 weeks followed by Endocrine Therapy for 24 weeks.","label":"Arm A Tamoxifen followed by Endocrine Therapy","type":"EXPERIMENTAL"},{"description":"Letrozole is given in the Window of Treatment phase for 2 weeks followed by Endocrine Therapy for 24 weeks.","label":"Arm B Letrozole Followed By Endocrine Therapy","type":"EXPERIMENTAL"},{"description":"Tamoxifen is given in the Window of Treatment phase for 2 weeks followed by Endocrine Therapy in combination with Palbociclib for 24 weeks.","label":"Tamoxifen Followed By Endocrine Therapy and Palbociclib","type":"EXPERIMENTAL"},{"description":"Letrozole is given in the Window of Treatment phase for 2 weeks followed by Endocrine Therapy in combination with Palbociclib for 24 weeks.","label":"Letrozole Followed By Endocrine Therapy and Palbociclib","type":"EXPERIMENTAL"}],"collaborators":["Pfizer"],"completion_date":{"date":"2031-04","type":"ESTIMATED"},"conditions":["Breast Cancer"],"enrollment":{"count":195,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Letrozole","otherNames":["Femara"],"type":"DRUG"},{"name":"Tamoxifen","otherNames":["Soltanox"],"type":"DRUG"},{"name":"Palbociclib","otherNames":["Ibrance"],"type":"DRUG"},{"name":"Endocrine Therapy","otherNames":["Nolvadex"],"type":"DRUG"}],"last_update":"2026-06-23","lead_sponsor":"Dana-Farber Cancer Institute","official_title":"Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS): A Randomized Phase II Study of Palbociclib With Letrozole Versus Letrozole Alone for Invasive Lobular Carcinoma and Invasive Ductal Carcinoma","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2022-02","type":"ACTUAL"},"primary_outcomes":[{"measure":"Difference in Anti-proliferative Activity of Patients Given Letrozole Versus Tamoxifen During the Window Phase","timeFrame":"baseline to day 15"},{"measure":"Pathologic Complete Response (pCR) of Patients Given Endocrine Therapy Plus Palbociclib and of Endocrine Therapy Alone During the Treatment Phase","timeFrame":"day 15 to 24 weeks"}],"references":[{"citation":"Grinshpun A, Dustin D, Cai M, Hughes M, DiLullo M, Moore M, Yardley D, Mayer IA, Symmans WF, Mayer EL, Winer EP, Lin NU, Tolaney SM, Metzger O, Jeselsohn R. Circulating tumor DNA in neoadjuvant endocrine therapy for early breast cancer. ESMO Open. 2026 Mar;11(3):106067. doi: 10.1016/j.esmoop.2026.106067. Epub 2026 Feb 10.","pmid":"41672025","type":"DERIVED"},{"citation":"Weiss A, Jin Q, Tayob N, Wrabel E, DeMeo M, Carter J, Constantine M, Faggen M, Block C, Fenton MA, Lo KMS, Openshaw T, Yardley D, Kennedy L, Bedrosian I, Mittendorf EA, Jeselsohn R, Metzger Filho O, King TA. Axillary Management and Outcomes After Neoadjuvant Endocrine Therapy in the Randomized PELOPS Trial. Ann Surg Oncol. 2026 Mar;33(3):2275-2283. doi: 10.1245/s10434-025-18697-5. Epub 2025 Nov 23.","pmid":"41276768","type":"DERIVED"},{"citation":"Weiss A, Revette A, Nava-Coulter B, Mittendorf EA, Filho OM, King TA. Surgeon Perspectives on Axillary Management Following Neoadjuvant Endocrine Therapy: Results from a Qualitative Substudy of the PELOPS Trial. Ann Surg Oncol. 2026 Mar;33(3):2267-2274. doi: 10.1245/s10434-025-18695-7. Epub 2025 Nov 21.","pmid":"41272386","type":"DERIVED"},{"citation":"Hermida-Prado F, Xie Y, Sherman S, Nagy Z, Russo D, Akhshi T, Chu Z, Feit A, Campisi M, Chen M, Nardone A, Guarducci C, Lim K, Font-Tello A, Lee I, Garcia-Pedrero J, Canadas I, Agudo J, Huang Y, Sella T, Jin Q, Tayob N, Mittendorf EA, Tolaney SM, Qiu X, Long H, Symmans WF, Lin JR, Santagata S, Bedrosian I, Yardley DA, Mayer IA, Richardson ET, Oliveira G, Wu CJ, Schuster EF, Dowsett M, Welm AL, Barbie D, Metzger O, Jeselsohn R. Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor-Positive Breast Cancer. Cancer Res. 2023 Oct 2;83(19):3284-3304. doi: 10.1158/0008-5472.CAN-23-1711.","pmid":"37450351","type":"DERIVED"}],"start_date":{"date":"2016-05-24","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS)","url":"https://clinicaltrials.gov/study/NCT02764541"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/pelops-nct02764541"}